The projected top performers are:
1. Actavis, a pharmaceutical company which successfully implemented the tax inversion strategy.
2. Perrigo Company Public Limited, a specialty pharmaceutical company in the process of tax inversion.
3. Merck & Co., a company in the major pharma sector.
4. Celgene, a biotech company focused on new therapies requiring collaboration.
5. Karyopharm Therapeutics, a small-mid-cap biotech company focused on cancer treatment in addition to other major diseases.
6. Thermo Fisher Scientific, which serves scientific endeavors.
7. Medtronic, a medical device company with a focus on orthopedics, which is also pursuing a tax inversion strategy.
8. Cigna, a healthcare insurance company expected to “face the least headwinds” when compared to peers.
More articles on healthcare:
Siouxland Surgery Center
ASC stock report—5 key company updates
32 ASC acquisitions in 2014
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
